Danaher (DHR) revenue tops expectations on strong respiratory testing demand

Danaher (NYSE: DHR) shares fell over 2% Tuesday despite the company's third-quarter earnings and revenue topping consensus expectations.

The company reported Q3 EPS of $2.02, $0.25 better than the analyst estimate of $1.77, while revenue for the quarter came in at $6.9 billion, down 10.5% YoY, but above the consensus estimate of $6.6 billion.

The company said higher respiratory testing revenue more than offset slightly softer-than-anticipated demand in Life Sciences. "DBS-driven execution also enabled us to deliver better-than-expected earnings and cash flow in what remains a challenging operating environment," commented Rainer Blair, DHR's President and Chief Executive Officer.

"With our differentiated portfolio and commitment to continuous improvement, we have a unique opportunity to help solve many of the world's most critical health care challenges while building meaningful long-term shareholder value," added Blair.

Looking ahead to Q4, the company anticipates adjusted base business core revenue from continuing operations will be down mid-single digits year-over-year. For the full-year 2023, it anticipates that adjusted base business core revenue from continuing operations "will be down slightly year-over-year."

By Sam Boughedda

You May Also Be Interested In

• Piper Sandler Starts Danaher (DHR) at Neutral
• Lands' End (LE) Tops Q1 EPS by 8c ; Offers Guidance
• Sirius XM (SIRI) to Join S&P MidCap 400